Robert F. Werner Sells 1,448 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the sale, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Twist Bioscience Stock Down 0.3 %

Shares of NASDAQ:TWST opened at $45.40 on Friday. The firm has a fifty day moving average of $43.69 and a two-hundred day moving average of $45.64. Twist Bioscience Co. has a 12-month low of $15.85 and a 12-month high of $60.90. The firm has a market capitalization of $2.66 billion, a P/E ratio of -11.88 and a beta of 1.78.

Analyst Ratings Changes

Several analysts have issued reports on TWST shares. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Finally, Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. American International Group Inc. increased its position in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after purchasing an additional 213 shares during the last quarter. Caprock Group LLC increased its holdings in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after buying an additional 220 shares during the last quarter. Signaturefd LLC increased its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. Arizona State Retirement System raised its position in Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after acquiring an additional 308 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after acquiring an additional 312 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.